These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30482063)

  • 1. Emerging drugs for the treatment of Dravet syndrome.
    Brigo F; Striano P; Balagura G; Belcastro V
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):261-269. PubMed ID: 30482063
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic advances in Dravet syndrome: a targeted literature review.
    Strzelczyk A; Schubert-Bast S
    Expert Rev Neurother; 2020 Oct; 20(10):1065-1079. PubMed ID: 32799683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing Landscape of Dravet Syndrome Management: An Overview.
    Samanta D
    Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
    Schoonjans AS; Ceulemans B
    Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real-world study.
    Gjerulfsen CE; Nikanorova M; Olofsson K; Johannessen Landmark C; Rubboli G; Møller RS
    Epilepsia Open; 2024 Oct; 9(5):1891-1900. PubMed ID: 39140199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
    Lopez JC; Pare JR; Blackmer AB; Orth LE
    J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
    Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis.
    Sharawat IK; Panda PK; Kasinathan A; Panda P; Dawman L; Joshi K
    Seizure; 2021 Feb; 85():119-126. PubMed ID: 33461030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
    Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
    Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.
    Polster T
    Epilepsy Behav; 2019 Feb; 91():99-102. PubMed ID: 30269941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery.
    Del Pozo A; Barker-Haliski M
    Exp Neurol; 2023 Feb; 360():114288. PubMed ID: 36471511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
    Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
    Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.
    Aderinto N; Olatunji G; Kokori E; Ajayi YI; Akinmoju O; Ayedun AS; Ayoola OI; Aderinto NO
    Eur J Med Res; 2024 Mar; 29(1):182. PubMed ID: 38500226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
    Zhang L; Li W; Wang C
    Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
    Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
    Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.